05.18.20

Oculis Reports Topline Data From Phase 2 Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgery

Source: Oculis

05.07.20

Oculis to Present Results From Its Phase 2 Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery

Source: Oculis

02.10.20

Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)

Source: Oculis

10.07.19

Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Source: Oculis

09.17.19

Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Board

Source: Oculis

01.04.19

Oculis In-Licenses Phase 2 Topical Anti-TNF Alpha Antibody From Novartis

Source: Oculis

01.04.19

Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseases

Source: Oculis

11.20.18

Oculis Appoints New Members of Senior Management Team

Source: Oculis

09.25.18

Oculis Appoints Pravin U. Dugel, MD, Chairman of its Scientific Advisory Board

Source: Oculis

09.24.18

Oculis Appoints Pravin U. Dugel, MD, Chairman of Scientific Advisory Board

Source: Oculis

View more stories